Log in

NASDAQ:NVIV - Invivo Therapeutics Stock Price, Forecast & News

$0.16
+0.01 (+6.67 %)
(As of 12/8/2019 01:39 PM ET)
Today's Range
$0.15
Now: $0.16
$0.16
50-Day Range
$0.13
MA: $0.34
$0.49
52-Week Range
$0.12
Now: $0.16
$2.06
Volume478,101 shs
Average Volume884,101 shs
Market Capitalization$2.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.73 per share

Profitability

Net Income$-23,420,000.00

Miscellaneous

Employees6
Market Cap$2.64 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.


Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Invivo Therapeutics shares reverse split on Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) issued its quarterly earnings results on Friday, November, 8th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.33) by $0.04. View Invivo Therapeutics' Earnings History.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Invivo Therapeutics.

Has Invivo Therapeutics been receiving favorable news coverage?

News articles about NVIV stock have trended extremely positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Invivo Therapeutics earned a coverage optimism score of 5.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Invivo Therapeutics.

Are investors shorting Invivo Therapeutics?

Invivo Therapeutics saw a decrease in short interest in October. As of October 15th, there was short interest totalling 14,500 shares, a decrease of 15.2% from the September 15th total of 17,100 shares. Based on an average daily volume of 35,900 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company's stock are sold short. View Invivo Therapeutics' Current Options Chain.

Who are some of Invivo Therapeutics' key competitors?

What other stocks do shareholders of Invivo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invivo Therapeutics investors own include Anavex Life Sciences (AVXL), iShares US Preferred Stock ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Ophthotech (OPHT), Gilead Sciences (GILD), Apollo Investment (AINV), TrovaGene (TROV), Celgene (CELG) and Bellicum Pharmaceuticals (BLCM).

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the folowing people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
  • Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
  • Mr. William D'Agostino PE, Sr. VP of Operations

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $0.16.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $2.64 million. The biotechnology company earns $-23,420,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Invivo Therapeutics employs 6 workers across the globe.View Additional Information About Invivo Therapeutics.

What is Invivo Therapeutics' official website?

The official website for Invivo Therapeutics is http://www.invivotherapeutics.com/.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Monthly Dividend Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel